Considerations for using Natalizumab treatment in patients with a history of choroidal melanoma.

Natalizumab is a monoclonal antibody licensed for the treatment of relapsing-remitting multiple sclerosis (RRMS). It is known to increase the potential risk of developing progressive multifocal leukoencephalopathy (PML). There is current debate in the literature regarding its association with malignant melanoma.

In Vivo Expansion of Regulatory T Cells by Low-Dose Interleukin-2 Treatment Increases Allograft Survival in Corneal Transplantation.

Background: Corneal allograft survival dramatically decreases in hosts with inflamed or vascularized recipient beds. We have previously shown that in rejected corneal allografts regulatory T cells (Treg) demonstrate diminished Foxp3 expression and immunoregulatory function. Treatment with low doses of IL-2 selectively expands Treg and has been proposed for the treatment of autoimmune diseases.

Marginal corneal vascular arcades.

Purpose: To determine the metrics of the marginal corneal vascular arcades (MCA).

Methods: The MCA and filling pattern was investigated using indocyanine green dye angiography (ICGA) in the fellow eye of patients with treated unilateral keratitis. Images were acquired using a scanning laser ophthalmoscope.